Postponed clinical trials affect ALK finances – central phase III trials have been delayed
The Monday guidance upgrade from allergy company ALK, which was confirmed on Wednesday morning, especially happened because sales had been better than expected, but also due to a series of savings and necessary postponements of clinical trials, such as the crucial Chinese phase III trial, which was meant to start in August, explains CEO Carsten Hellmann.
.jpg)
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Monday afternoon, Danish allergy company ALK upgraded the guidance for its main figures relating to revenue and earnings ahead of today's presentation of the firm's quarterly report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK increases sales in Q2, but operating result decreases
For subscribers
ALK upgrades guidance following convincing sales and savings
For subscribers
.jpg)
.jpg&w=384&q=75)
